Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of butylphthalide in patients with vascular cognitive impairment

Meng Guo¹, Lirong Wu²

¹Department of Neurology, The Thirteenth People's Hospital of Chongqing, Chongqing 400053, China; ²Department of Neurology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing 400021, China.

For correspondence:- Lirong Wu Email: wulirong1978@cdutcm.edu.cn Tel:+8613101273775

Accepted: 3 October 2022 Published: 28 October 2022

Citation: Guo M, Wu L. Effect of butylphthalide in patients with vascular cognitive impairment. Trop J Pharm Res 2022; 21(10):2227-2231 doi: 10.4314/tjpr.v21i10.25

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To study the effects of butylphthalide in patients with vascular cognitive impairment.

Method: Sixty patients with vascular cognitive impairment were randomly divided into control group and butylphthalide (NBP) group (n = 30). Control group received blood pressure control, blood sugar control, and lipid-lowering therapies, while NBP group received butylphthalide capsules (200 mg, thrice daily). Treatments in both groups lasted for 14 days. Thereafter, Hasegawa Dementia Scale (HDS), Mini-Mental State Examination (MMSE), Activities of Daily Living Scale (ADL), and event-related potential (P300) were used to evaluate the effects of butylphthalide treatment.

Result: Following 14 days of treatment, HDS, MMSE and ADL scores of NBP group were significantly higher than those of the control group (p < 0.05). The P300 latency of NBP group was shorter than that of control group, while P300 amplitude was higher than that of control group (p < 0.05).

Conclusion: Butylphthalide treatment achieves higher scores of HDS, MMSE and ADL scores, but shorter P300 latency. These results provided good evidence of the effectiveness of butylphthalide therapy in the management of vascular cognitive impairment. However, further clinical trials are recommended prior to application in clinical practice.

Keywords: Î²utylphthalide (NBP), Vascular cognitive dysfunction, Hasegawa Dementia Scale, Activities of Daily Living Scale, event-related potential